Paul Sekhri will join Teva Pharmaceutical Industries as Group Executive Vice President, Global Business Development and Chief Strategy Officer on 15 June.
Sekhri has more than 25 years’ experience in the life sciences industry, including business development, business strategy, general management, drug development, and commercial strategy. In his new role, he will oversee Teva’s Strategy and Business Development group. He will join Teva’s leadership team, and be based at the company’s headquarters in Israel.
Most recently Sekhri was Operating Partner and Head, Biotech Ops Group at TPG Biotech, the life science venture arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life science firms. During his tenure, he served on the board of five TPG healthcare companies, including as chairman of a portfolio company in the branded generics space, and as consulting advisor for diverse other life science companies within the portfolio. Prior to this, Sekhri founded and was President and Chief Executive of Cerimon Pharmaceuticals, focused on autoimmune diseases and pain management.
He has also been President and Chief Business Officer of Ariad Pharmaceuticals.
Prior to this, he held senior positions at Novartis Pharma, including as Senior Vice President and Head, Global Search and Evaluation and M&A. He has also held managerial positions at Millipore Corporation and PerSeptive Biosystems.
